Lv Yaochun, Qian Zhengpeng, Wu Dewang, Zhu Chengzhang, Zhang Jipeng, Ning Yeping, Du Binbin
Gansu Clinical Medical Research Center for Anorectal Diseases, Lanzhou, Gansu, China.
The First Clinical Medical College, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Front Oncol. 2025 Mar 14;15:1473620. doi: 10.3389/fonc.2025.1473620. eCollection 2025.
Human epidermal growth factor receptor 2 (HER2) is an anti-cancer drug target for colon cancer. Among patients with colorectal malignancy (colorectal cancer, CRC), those with HER2 mutations have a poor overall prognosis and a significantly increased drug resistance. In recent years, anti-HER2 therapeutic drugs have developed rapidly. According to several clinical studies and case reports, anti-HER2 therapy, as an emerging anti-cancer approach, plays a crucial role in the treatment of HER2-positive CRC patients. Here, we present a case of HER2-positive descending colon cancer with peritoneal metastasis. The patient is a 26-year-old male, diagnosed with malignant tumor of the descending colon with peritoneal metastasis in April 2020. After multiple treatment modalities, the disease progressed. After chemotherapy with Trastuzumab Deruxtecan (T-DXd/DS-8201), the metastatic foci significantly shrank, and after surgical resection, a tumor-free state (NED) was achieved. Up to now, the patient's survival period has reached 56 months.
人表皮生长因子受体2（HER2）是结肠癌的一个抗癌药物靶点。在结直肠恶性肿瘤（结直肠癌，CRC）患者中，那些存在HER2突变的患者总体预后较差，且耐药性显著增加。近年来，抗HER2治疗药物发展迅速。根据多项临床研究和病例报告，抗HER2治疗作为一种新兴的抗癌方法，在HER2阳性CRC患者的治疗中发挥着关键作用。在此，我们报告一例HER2阳性降结肠癌伴腹膜转移的病例。该患者为一名26岁男性，于2020年4月被诊断为降结肠恶性肿瘤伴腹膜转移。经过多种治疗方式后，疾病进展。在用曲妥珠单抗德鲁替康（T-DXd/DS-8201）化疗后，转移灶明显缩小，手术切除后达到无瘤状态（NED）。截至目前，患者生存期已达56个月。
